Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24942298
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24942298
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Hematol+Malig+Rep
2014 ; 9
(3
): 284-93
Nephropedia Template TP
Curr Hematol Malig Rep
2014[Sep]; 9
(3
): 284-93
PMID24942298
show ga
Although Hodgkin lymphoma (HL) is largely curable with first-line therapy,
approximately one-third of patients will not have a complete response to
frontline treatment or will subsequently relapse. Only 50% of these patients will
be effectively salvaged with conventional therapies. The prognosis is
particularly poor for those patients with chemotherapy refractory disease, who
are unable to obtain even transient disease control, and for patients who relapse
following high dose chemotherapy and autologous stem cell transplant. In this
review, we summarize the most recent updates on the management of patients with
relapsed HL, the role of novel therapies such as brentuximab vedotin, and an
overview of promising new agents currently under investigation. We also discuss
the role of consolidation strategies such as high-dose chemotherapy and
autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic
stem cell transplant, and the need for new strategies in the elderly patient
population.
free
free
free
